NeuroVoices

The founder and chief scientific officer of Neurolutions discussed how the company’s newly approved chronic stroke rehabilitation system will provide expanded benefits to post-stroke patients.

The neurologist from Cleveland Clinic discussed his study presented at AAN 2021 involving the use of responsive neurostimulation in older adults with drug-resistant focal epilepsy and further expanding research in this space.

The assistant professor of neurology at the Weill Cornell Brain and Spine Center discussed his presentation at AAN 2021 evaluating racial disparities in smoking cessation among stroke survivors.

The professor of neurology at Mayo Clinic discussed the need for understanding more about how social determinants of health can impact epilepsy treatment delays.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed solutions to improve disparities in stroke care and the need for future research on social determinants of health.

The consultant in the department of neurology at Mayo Clinic detailed a number of topics surrounding Parkinson Disease Awareness Month, including the progress made in the last 2 decades.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed the abundance of research from the Florida Stroke Registry presented at ISC 2021.

The duo from Montefiore Medical Center discussed a variety of topics surrounding an effort to improve seizure diagnosis and classification in newborns.

The postdoctoral researcher at Columbia University detailed a number of topics regarding the impact concealing multiple sclerosis diagnosis can have on a patient.

The clinical research coordinator at Massachusetts General Hospital discussed his presentation from ACTRIMS 2021 on electronic pill bottle monitoring to promote MS medication adherence.

The duo from Cleveland Clinic discussed their recently initiated study which will evaluate the neuroprotective features of home-based intervention in high-risk individuals for Alzheimer disease.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed a recently initiated study that will look at the FDA-approved cancer drug lenalidomide for the treatment of Alzheimer disease.

The duo from Vanderbilt University shared background on their recently published study that found novel associations between functional seizures, cerebrovascular disease, and other psychiatric disorders.

Barbara Karp, MD, and Sharon Meropol, MD, discuss the recently launched NeuroCOVID databank from the NIH, which will track neurologic symptoms associated with COVID-19.

The director of the Massachusetts General Hospital ALS Care Center sat down to discuss ‘The Data is Here’ campaign from Answer ALS, the world’s largest open-sourced ALS data portal.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine detailed his study on the correlations between sleep and cognitive decline in middle-aged Hispanics.

The clinical fellow at Massachusetts General Hospital detailed his research on neurology resident EEG education, and the increased need for more consistency throughout programs.

Raymond Sanchez, MD, chief medical officer of Cerevel Therapeutics, discussed tavapadon, a drug intended to treat Parkinson disease that is currently being tested in a slew of clinical trials.

Jennifer Robblee, MD, neurologist, Barrow Neurological Institute, shares her takeaways about how migraine care shifted this year and how it may continue to shift going forward.

The assistant professor of neurology and anesthesiology at Harvard Medical School detailed the findings of a phase 2 trial using ezogabine, a drug once FDA-approved to treat epilepsy, in patients with ALS.

Eric Segal, MD, director of pediatric epilepsy, HMH Hackensack University Medical Center, detailed his study on diazepam nasal spray in patients with and without antiseizure medications.

Christian Meisel, MD, PhD, department of neurology, Universitätsmedizin Berlin, and Berlin Institute of Health, discussed the landscape for devices that forecast seizures, including the use of multi-modal wristband sensors.

The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center sat down to discuss a multitude of topics surrounding Infantile Spasms Awareness Week.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.

The vice president of Clinical Research at Eisai provides updates on the MOMENTUM trials which will examine lorcaserin as a potential treatment for patients with Dravet syndrome.

The chief scientific officer of the Parkinson’s Foundation discussed how the PD GENEration initiative tackles 1 of the greatest unmet needs for patients with Parkinson disease.

Joe Verghese, MBBS, MS, details the research being conducted on motoric cognitive risk syndrome and noninvasive brain stimulation in Alzheimer disease.

The professor of neurology at the NYU Langone Grossman School of Medicine discussed a recent study she and colleagues conducted on new neurological disorders in patients with COVID-19.